BioSpace News Archive

Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the first quarter of 2020

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2019, after the U.S. markets close on February 6, 2020.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,448,278 shares of its common stock, at a purchase price per share of $1.45, in a registered direct offering priced at-the-marked under the Nasdaq rules.

Genentech, a member of the Roche Group, announced that the Phase III IMvigor010 study evaluating Tecentriq® as an adjuvant monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time.

Technavio has announced its latest market research report titled global cold chain logistics market for pharmaceuticals industry 2020-2024.

CStone Pharmaceuticals recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an oral multi-kinase inhibitor developed by Bayer Healthcare LLC.

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate plaque psoriasis

The National Institutes of Health’s All of Us Journey is visiting multiple locations in Texas throughout January and February to educate communities about the opportunity to participate in a historic medical research effort.

Bureau Veritas a world-leader in testing, inspection, and certification (TIC) services, today announced that Ron Stupi has been appointed to senior vice president and chief operating officer of its building and infrastructure (B&I) team, part of its Commodities, Infrastructure, and Facilities (CIF) division in North America, effective immediately.